1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Idiopathic Pulmonary Fibrosis Market: Product Outlook
4. Global Idiopathic Pulmonary Fibrosis Market: Sizing and Forecast
4.1 Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026
Table 1: Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 3: GDP per Capita Growth (annual %), 2015-2019
Table 4: World Population 65 Years & Above (% of Total), 2015-2019
Table 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Table 7: Global IPF - Number of Drugs by Phase
4.2 Impact of COVID-19 on Global Idiopathic Pulmonary Fibrosis Market
5. Global Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, End-User
5.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Drug Type
Table 8: Global Idiopathic Pulmonary Fibrosis Market- By Drug Type Market Share, 2020 & 2026
5.1.1 Nintedanib - Market Size and Forecast (2016-2026)
Table 9: Global Idiopathic Pulmonary Fibrosis Market- By Nintedanib, By Value (USD Million), 2016-2026
5.1.2 Pirfenidone - Market Size and Forecast (2016-2026)
Table 10: Global Idiopathic Pulmonary Fibrosis Market- By Pirfenidone, By Value (USD Million), 2016-2026
5.1.3 Others - Market Size and Forecast (2016-2026)
Table 11: Global Idiopathic Pulmonary Fibrosis Market- By Others, By Value (USD Million), 2016-2026
5.2 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By End User
Table 12: Global Idiopathic Pulmonary Fibrosis Market- By End User Market Share, 2020 & 2026
5.2.1 Hospitals and Clinics - Market Size and Forecast (2016-2026)
Table 13: Global Idiopathic Pulmonary Fibrosis Market- By Hospitals and Clinics, By Value (USD Million), 2016-2026
5.2.2 Academics and Research Organization - Market Size and Forecast (2016-2026)
Table 14: Global Idiopathic Pulmonary Fibrosis Market- By Academics and Research Organization, By Value (USD Million), 2016-2026
5.2.3 Others - Market Size and Forecast (2016-2026)
Table 15: Global Idiopathic Pulmonary Fibrosis Market- By Others, By Value (USD Million), 2016-2026
6. Global Idiopathic Pulmonary Fibrosis Market: Regional Analysis
6.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Region
Table 16: Global Idiopathic Pulmonary Fibrosis Market- By Region Market Share, 2020 & 2026
7. North America Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
7.1 North America Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 17: North America Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 18: North America Current health expenditure(% of GDP)2014-2018
Table 19: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 20: North America Population ages 65 and above (% of Total Population), 2016-2020
7.2 North America Idiopathic Pulmonary Fibrosis Market - Prominent Companies
Table 21: North America Idiopathic Pulmonary Fibrosis company market share (%), 2020
7.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone and Others)
Table 22: North America Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
7.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization and Others)
Table 23: North America Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
7.5 North America Idiopathic Pulmonary Fibrosis Market: Country Analysis
7.6 Market Opportunity Chart of North America Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
Table 24: Market Opportunity Chart of North America Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year 2016-2026)
7.7 Competitive Scenario of North America Idiopathic Pulmonary Fibrosis Market: By Country
Table 25: North America Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026
7.8 United States Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 26: United States Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 27: United States Distribution of Diagnosed IPF Patients, 2020
Table 28: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 29: United States Population aged 65 and above (% of Total Population), 2016-2020
7.9 United States Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
Table 30: United States Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Table 31: United States Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
7.10 Canada Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 32: Canada Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 33: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 34: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 35: Canada Population aged 65 and above (% of Total Population), 2016-2020
7.11 Canada Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
Table 36: Canada Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Table 37: Canada Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
8. Europe Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
8.1 Europe Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 38: Europe Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 39: Europe Distribution of Diagnosed IPF Patients, 2020
Table 40: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 41: European Countries Population ages 65 and above (% of total Population), 2020
8.2 Europe Idiopathic Pulmonary Fibrosis Market - Prominent Companies
Table 42: Europe Idiopathic Pulmonary Fibrosis company market share (%), 2020
8.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone and Others)
Table 43: Europe Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
8.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization and Others)
Table 44: Europe Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
8.5 Europe Idiopathic Pulmonary Fibrosis Market: Country Analysis
8.6 Market Opportunity Chart of Europe Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
Table 45: Market Opportunity Chart of Europe Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year 2016-2026)
8.7 Competitive Scenario of Europe Idiopathic Pulmonary Fibrosis Market: By Country
Table 46: Europe Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026
8.8 Germany Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 47: Germany Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 48: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 49: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 50: Germany Urban population growth,(Annual %) 2015-2020 (In %)
8.9 Germany Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
Table 51: Germany Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Table 52: Germany Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
8.10 United Kingdom Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 53: United Kingdom Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 54: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 55: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 56: United Kingdom Population ages 65 and above (% of Total Population), 2016-20
8.11 United Kingdom Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
Table 57: United Kingdom Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Table 58: United Kingdom Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
8.12 France Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 59: France Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 60: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 61: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 62: France Population ages 65 and above (% of Total Population), 2016-20
8.13 France Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
Table 63: France Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Table 64: France Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
8.14 Italy Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 65: Italy Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 66: Italy Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 67: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 68: Italy Population ages 65 and above (% of Total Population), 2016-20
8.15 Italy Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
Table 69: Italy Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Table 70: Italy Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
8.16 Spain Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 71: Spain Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 72: Spain Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 73: Spain Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 74: Spain Urban population Growth (Annual %), 2016-2020 (In %)
8.17 Spain Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
Table 75: Spain Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Table 76: Spain Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
9. Asia Pacific Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
9.1 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
able 77: Asia Pacific Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 78: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 79: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 80: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
9.2 Asia Pacific Idiopathic Pulmonary Fibrosis Market - Prominent Companies
9.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone and Others)
Table 81: Asia Pacific Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
9.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization and Others)
Table 82: Asia Pacific Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
9.5 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Country Analysis
9.6 Market Opportunity Chart of Asia Pacific Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
Table 83: Market Opportunity Chart of APAC Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year-2026)
9.7 Competitive Scenario of Asia Pacific Idiopathic Pulmonary Fibrosis Market: By Country
Table 84: APAC Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026
9.8 China Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 85: China Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 86: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 87: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 88: China Population ages 65 and above (% of Total Population), 2016-20
9.9 China Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
Table 89: China Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Table 90: China Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
9.10 Japan Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 90: China Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Table 91: Japan Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 92: Japan Europe Distribution of Diagnosed IPF Patients, 2020
Table 93: Japan Current Healthcare Expenditure as a percentage of GDP, 2015-2018 (In %)
Table 94: Japan Population ages 65 and above (% of Total Population), 2016-20
9.11 Japan Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
Table 95: Japan Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Table 96: Japan Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
9.12 India Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
Table 97: India Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Table 98: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Table 99: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Table 100: India Population ages 65 and above (% of Total Population), 2016-20
9.13 India Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
Table 101: India Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Table 102: India Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
10. Global Idiopathic Pulmonary Fibrosis Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Drug Type, 2026
Table 103: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By Drug Type (Year-2016-2026)
11.2 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By End User, 2026
Table 104: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By End User (Year 2016-2026)
11.3 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Region, 2026
Table 105: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By Region (Year 2016-2026)
12. Competitive Landscape
12.1 Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies
12.2 Market Share Analysis
Table 106: Global Idiopathic Pulmonary Fibrosis company market share
13. Company Analysis
13.1 AbbVie Inc.
Table 107: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
Table 108: AbbVie Inc. Net Income (USD Million), 2016-2020
Table 109: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
Table 110: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
13.2 Bristol-Myers Squibb
Table 111: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Table 112: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Table 113: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Table 114: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
13.3 F. Hoffman-La Roche Ltd.
Table 115: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Table 116: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Table 117: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Table 118: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
13.4 Boehringer Ingelheim
Table 119: Boehringer Ingelheim Revenues, 2016-2020 (USD Million)
Table 120: Boehringer Ingelheim Net Income/Loss, 2016-2020 (USD Million)
Table 121: Boehringer Ingelheim Sales Revenue Split, By Business Segment (%), FY2020
Table 122: Boehringer Ingelheim Sales Revenue Split, By Geography Segment (%), FY2020
13.5 Merck KGaA
Table 123: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Table 124: Merck KGaA Gross Profit, 2016-2020 (USD Million)
Table 125: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
Table 126: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
13.6 Gilead Sciences
Table 127: Gilead Sciences, Revenue, 2016-2020 (USD Million)
Table 128: Gilead Sciences, Net Income 2016-2020 (USD Million)
Table 129: Gilead Sciences, Revenue, By Business Segment (%), FY2020
Table 130: Gilead Sciences Revenue, By Geographical Segment (%), FY2020
13.7 Liminal Biosciences
Table 131: Liminal Biosciences, Revenue, 2016-2020 (USD Million)
Table 132: Liminal Biosciences, Net Loss 2016-2020 (USD Million)
Table 133: Liminal Biosciences, Revenue, By Business Segment (%), FY2020
Table 134: Liminal Biosciences Revenue, By Geographical Segment (%), FY2020
13.8 Cipla
Table 135: Cipla Sales Revenues, 2016-2020 (USD Million)
Table 136: Cipla sales Revenues, By Business Segment (%), FY2020
Table 137: Cipla sales Revenue, By Geographical Segment (%), FY2020
13.9 Galapagos NV
Table 138: Galapagos NV Annual Sales Revenue (USD Million), 2016-2020
Table 139: Galapagos NV sales Revenue, By Geographical Segment (%), FY2020
13.10 FibroGen
Table 140: FibroGen, Revenue, 2016-2020 (USD Million)
Table 141: FibroGen, Net Loss 2016-2020 (USD Million)
13.11 Medicinova Inc.
Table 142: MediciNova, Inc., Total Operating Expenses, 2015-2019 (USD Million)
Table 143: MediciNova Inc., Net Loss 2015-2019 (USD Million)